Korea Joongang Daily
Korea JoongAng Daily

Samsung Biologics breaks profit records as it expands production capacity

Samsung Biologics posted a record annual operating profit of more than 2 trillion won ($1.4 billion) in 2025, driven by expanded production capacity and a weaker won, the company said on Wednesday.

2026-01-21

Samsung Biologics to launch ADC drug product service in 2027

Samsung Biologics is preparing to launch an antibody-drug conjugate (ADC) drug product service in the first quarter of 2027, reflecting its efforts to more closely link drug development with downstream manufacturing.

2026-01-18

Samsung Biologics looks to scale up U.S. manufacturing in Maryland

Samsung Biologics is seeking to strengthen its U.S. footprint by expanding capacity at its recently acquired manufacturing facility in Rockville, Maryland, as it seeks to meet growing customer demand for U.S.-based production.

2026-01-14

Korean biotech firms aim to expand U.S. presence at J.P. Morgan Healthcare Conference

At the 44th J.P. Morgan Healthcare Conference, Korean biotech firms are making efforts to enhance their presence in the U.S. market.

2026-01-13

Samsung Biologics to acquire U.S. drug manufacturing facility from GSK

Samsung Biologics will acquire a drug manufacturing facility in the United States from GlaxoSmithKline for $280 million, marking its first production foothold in the country as it seeks to strengthen supply chain resilience.

2025-12-22

Samsung Biologics reports record-breaking $1.1 billion in revenue in Q3

Samsung Biologics reported record earnings for the third quarter, posting more than 1.6 trillion won ($1.1 billion) in revenue, driven by large-scale contract wins with global pharmaceutical firms and strong sales of biosimilars.

2025-10-28

Samsung Biologics inks $1.29 billion deal as Korean biotech firms scramble amid Trump tariff threat

Samsung Biologics secured a $1.29 billion contract with a U.S. pharmaceutical firm, boosting cumulative orders this year to 5.24 trillion won. Companies like Lotte Biologics and Celltrion also reported significant contracts amid tariff concerns.

2025-09-09

Samsung Biologics signs 1.8 trillion won deal with U.S. pharma firm

Samsung Biologics, Korea's leading biotech firm, said Tuesday it has secured a 1.8 trillion-won ($1.29 billion) contract to provide manufacturing services for a U.S. pharmaceutical company through 2029.

2025-09-09

U.S. trade deal has pharma firms on edge despite 'most favored nation' status

Following the Korea-U.S. tariff negotiations on Wednesday, the Korean government said Washington has promised most-favored-nation (MFN) treatment under its upcoming pharmaceutical tariff policy.

2025-07-31

Samsung Biologics employee sentenced to three years for stealing confidential documents

A former Samsung Biologics employee was sentenced to three years in prison for illegally taking company documents that included "national core technologies" in biotechnology. The court immediately remanded the worker into custody.

2025-07-11